Promis neurosciences to participate in guggenheim securities smid cap biotech conference

Cambridge, massachusetts, jan. 29, 2025 (globe newswire) -- promis neurosciences, inc. (nasdaq: pmn), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as alzheimer's disease (ad), amyotrophic lateral sclerosis (als) and multiple system atrophy (msa), today announced that neil warma, chief executive officer of promis neurosciences, will participate in a fireside chat at the guggenheim securities smid cap biotech conference on wednesday, february 5, 2025 at 1:30 p.m. et in new york, ny.
SMID Ratings Summary
SMID Quant Ranking